When designing a biological therapeutic agent, it is critically important to establish the feasibility of achieving a desired target product profile (TPP) as early in the program as possible, typically at the ‘New Target Proposal Stage’ or at the start of Lead Identification. In this case study, our partner was at the target selection stage for a bispecific agent that would hopefully work across four potential indications. They had confirmed one target, the anchor epitope (Target A), but were undecided as to the second target (Target B); based on the biology of their indications, they had 90 potential targets from which to choose, all with equally compelling biology as the project was very early (Figure 1).
To be competitive, according to the TPP, the ideal dosing regimen was monthly, or less frequent, subcutaneous (SC) administration, and acceptable was weekly SC dosing. Due to resource constraints, they needed to reduce the number of potential combinations to a low number. The partner requested our help in prioritizing a small set of target combinations to pursue further.
- We reduced the search space from 90 to 4 viable potential target B options. This resulted in developing a platform and projects that could be executed in a timely fashion and reasonable costs.
- By significantly reducing the number of targets to explore, our partners was able to eliminate dead ends before significant investment, saving potentially millions of dollars and years of time and accelerate timelines for their promising candidates